Skip to content
Markets News
Earnings1 min read

Mankind Pharma Profit Jumps 37.7% as Shares Extend Gains

Makkler Newsroom
October 27, 2026 · Based on reporting by The Economic Times, Business Standard

The drugmaker reported higher quarterly profit and revenue, while analysts flagged the need to sustain domestic growth in coming quarters.

Key takeaways

  • September-quarter profit rose 37.7% to ₹716 crore.
  • Revenue from operations increased to ₹4,338 crore.
  • Management kept its FY27 EBITDA margin guidance at 25.5% to 26.5%.

Mankind Pharma’s September-quarter profit rose 37.7% year over year to ₹716 crore, as revenue from operations increased to ₹4,338 crore from ₹3,697 crore a year earlier.

The company’s India business grew 14.8% to ₹3,657 crore, Business Standard reported. EBITDA rose 27.2% to ₹1,175 crore, and the margin improved to 27.1% from 25.0%.

Mankind shares rose in Tuesday trading. Business Standard reported an intraday gain of 6.5% on the BSE, extending Monday’s advance. As of 07:38 UTC Tuesday, the shares traded at ₹2,512.80, up 8.69% since the previous close.

Management retained its FY27 EBITDA margin guidance of 25.5% to 26.5% and forecast research and development spending at 2.8% to 3.0% of revenue, Business Standard reported.

JM Financial analysts said the quarter was seasonally favourable for companies with a large acute-drug business, and said sustained domestic performance in coming quarters remained important to watch. Systematix analysts cited improving domestic volumes, a higher chronic-drug contribution and export momentum as expected growth supports.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.